Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VERIFIED PROFILE UPDATE as of this month on OTC Markets page for BSSP fyi
Yep quite a few people loaded for a nice bounce here. Not too many liquid TRIPS are out there with under hundred million in the float. Let alone a Pink current company that is known to release news. Makes perfect sense for them to try and pump the share price up here at some point or release some solid news to increase PPS before continuing to dilute/potentially RS’ing again like many apparently fear. Trade the trade.
The other amendments were Series B, C and E preferred as well fyi. Had copies emailed to me from NVSOS a couple days ago. Merger updates via NVSOS or an 8k can literally happen at any time.
Exciting times ahead.
Nobody's selling. Was funny seeing a big chunk of shares come up on the ask earlier with the looks of enticing some selling, but came up dry. Reason people aren't buying like some want to see is because the majority who see the potential here have been loaded. Anyone else looking for shares understands that being patient can yield shares occasionally on the bid, but any real size seems to be picked up pretty quickly as thats really the only way to pick up over a million shares. As many already know, patience should pay the biggest dividends here, but to each their own.
New Clark County Update
previously:
05/13/2019 Motion
Judicial Officer
Hardy, Joe
Hearing Time
9:00 AM
Comment
Motion to Terminate Custodianship
Now this morning:
05/13/2019 Motion
Judicial Officer
Hardy, Joe
Hearing Time
9:00 AM
Result
Motion Granted
Comment
Motion to Terminate Custodianship
Parties Present
Petitioner
Attorney: Chasey, Peter L.
check the clark county page again, 5/20 cancel reason “vacated - case closed”
Thats the funny part, people didn’t even catch the “vacated- Case closed” part on that last update. All we are waiting for now are those highly anticipated “real” company updates :)
New Clark County update!!! Things are moving incredibly quick here :)
05/15/2019 Order
Comment
Order Discharging Custodian
05/16/2019 Notice of Entry of Order
Comment
Notice of Entry of Order
?
05/20/2019 Status Check
Judicial Officer
Hardy, Joe
Hearing Time
9:00 AM
Cancel Reason
Vacated - Case Closed
The entire OTC market is messed up today, Been trading it for years and have never seen a day where hundreds upon hundreds of tickers are getting hit with tiny dumps and causing traders to loose their butts on commission. Literally have never seen something like this across the OTC like today. Its causing tons of retail to pull bids and be much less aggressive.
Hey thats my tweet man smh lol
Holy, do you even know what your invested in?? LOL
Its actually pretty nice to see the spread tighten up a little bit as the days go. Shares seem to be continuing to transfer into stronger hands.
I agree that the quieter it is here in terms of the merging company, the better. A company appears scammy when they try to “hype” something up. A legit company knows their numbers will speak for themselves, and the valuation dislocation will adjust accordingly.
TRDX seems to have the nicest share structure in all of Lazar’s tickers, and I’m sure the company coming in is happy about the liquidity of this shell, as many other custodian plays can be much less tradable. It may just be the perfect storm for something beautiful from these levels :)
At the same time, one must prepare themselves in case it’s the opposite. With all the eyes and talk here, a company that has less revenue than the market was theoretically suspecting could create a less positive outcome. Obviously not hoping for that though!
SOS filing, new merge in https://
twitter.com/otcorbust/status/1118646278076821504?s=21
breakout imminent imo
$TRDX hourly looking mighty fine, gonna break outta that .0028 resistance level and wedge sooner or later🤓 pic.twitter.com/dpUKA6azlw
— BCtrades (@Because_Trades) April 17, 2019
$TRDX bigger picture outlook is exciting. This shell has the perfect share structure for a merge in of a big company, Lazar has moved much quicker than usual here. One of the easiest holds from these levels imo pic.twitter.com/eW5Iyj3XWq
— BCtrades (@Because_Trades) April 17, 2019
Not a problem at all, ever since the share block was added to OS I have been watching closer. Im pretty sure the update hit OTCre (where I saw it) after hours. If not it was near close as I was checking the custodian case update feed up until about 11am pacific time
Little update on OTC markets for TRDX, worth getting a discussion going on for people more experienced w/ Lazar plays.
Hmm $TRDX "shell risk" added overnight but not listed under Shell status changes on OTC markets compliance stats. Can definitely guarantee it was not there as of last night though. Anybody know if the ticker has been listed as a shell in the last couple of years? pic.twitter.com/xcZs6uuWXi
— BCtrades (@Because_Trades) March 25, 2019
Correct, not saying it's 100%, but again, it has been accurate once so it is definitely worth mentioning. If someone wants to go waisting their money on commissions to paint fake mm signals, go right ahead, don't think thats the best strategy to be honest lol
Correct, not saying it's 100%, but again, it has been accurate once so it is definitely worth mentioning. If someone wants to go waisting their money on commissions to paint fake mm signals, go right ahead, don't think thats the best strategy to be honest lol
A "prank" that was accurate to a dime a couple weeks ago, and can be quite often if you take note of it in the OTC.
Surprised nobody is mentioning the "911" trade that came up an hour or so ago. The last time one of those hit the Attorney letter and filings hit within 2 days.
Ignore the noise and stick to your game plan. Mine is to load as much of the float as my capital allows. Almost 2% so far ;)
Serious question, would typical RM updates from the company come via an 8k or PR, in this case on TRDX/David Lazar's side?
AS OF RIGHT NOW, TRDX is officially Pink Current! Just updated on OTC markets :)
Just fyi I noticed the "unable to contact" was removed at some point this morning on OTCMarkets page. It was there as of last night.
$TRDX "Unable to contact" removed from OTC markets. 👀 pic.twitter.com/c8IrsUQehI
— BCtrades (@Because_Trades) March 11, 2019
I should get one too, just broke my leg/ankle last weekend, painful as heck.
Sofpulse website UPDATED*
I check I believe 2 days ago and it was still the same old site, so within the last 24 hours it seems the updated website, or at least a version of it has gone live.
https://www.sofpulse.com
Agreed.
Hopefully using the money for better forms of "corporate awareness" as per the corporate update recently: "In support of better positioning Endonovo and its evolutionary technology in the market, we are in the process of initiating an ongoing and focused public relations and advertising campaign at the outset of the year. We are currently interviewing multiple firms to assess each firms capacity to most effectively reach the medical community and general public while properly articulating our products clinical capabilities to healthcare professionals."
Also, new mm today on L2 PAUL... I have never seen this mm in the 2 years I've been here, and can't find much online about them. Definitely will be noting changes in price action today and any going forward.
Dude he’s calling people on their home phones swearing and harassing them instead of having a lawyer deal with the situation. He’s handling it completely the wrong way. If i owned any shares in any of his companies, I would be incredibly hesitant to hold with that kind of unprofessionalism in charge. There will be a lot of investors that are now going to stay far away from his tickers due to his actions on Twitter. And who would want to invest longterm in a company that is influenced or in charge by such an unprofessional person. All my opinion, but am seriously worried for good people holding shares here that could easily be affected negatively by his selfish actions.
It's Alan! When was the last time we have seen a Form 4 with that guys name on it? Seriously have no idea, not anytime recently that's for sure.
Anything look a little different in that last form 4 that just came out?
I know right, I'm waiting for you know who to pop up with his daily dose of doom and gloom. Looking mighty strong today on the best corporate update I've ever heard from ENDV imo. This chart has been primed for a pop for quite a little while.
News out - Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
LOS ANGELES, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB:ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies brand, today announced the allowance for the patent application entitled DEVICES AND METHOD FOR TREATMENT OF DEGENERATIVE JOINT DISEASES WITH ELECTROMAGNETIC FIELDS by the U.S. Patent and Trademark Office. Endonovo will be including this technology under its WOUNDPULSE™brand.
Alan Collier, CEO of Endonovo Therapeutics, stated, "This Notice of Allowance highlights treatments with SofPulse™ brand, which allows patients to better manage pain without the adverse side effects of narcotics and anti-inflammatory medication. SofPulse™ brand reduces pain and edema and thereby decreases the requirement for medication post-surgery. With less pain and less medication, patients can stimulate the body's natural response to healing much quicker."
"With the opioid epidemic being so far-reaching, we believe SofPulse™ brand is an alternative that can be widely used. Our ongoing efforts have been very positive when speaking to clinicians and patients. I am pleased with our accomplishments throughout 2018 and believe in having secured Intellectual Property protection for WOUNDPULSE™ brand we can implement a strategic sales and marketing campaign. We continue to expand our relationships with our current distributors and in discussions with prospective partners. We are also building an internal sales team that can focus its efforts on hospitals, cosmetic surgery centers, physicians and surgeons. As such, we are modifying some old marketing material and creating new sales and marketing material which now can include the WOUNDPULSE™ brand.
For additional information visit www.sofpulse.com
https://www.nasdaq.com/press-release/endonovo-therapeutics-announces-receipt-of-notice-of-allowance-from-the-united-states-patent-and-20181218-00591
Don't lie Crozz...
These paid articles have been coming out for years, and throughout our past long-term downtrend. They never had any affect like they have had recently. Your statement is false that these articles are directly contributing to this. I am sure they are influencing it to an extent, but not anywhere near what you are saying.
The charts are looking incredibly nice here. I am sure thats bringing in volume, as well as the psychology here. A lot of longs sold, and now our ask has been noticeably thinned out. And after buying like yesterday, buying that HAS NEVER HAPPENED HERE like that, not even on the last so called "pump" you are referring to, confidence seems to be building based on price action.
Potential Catalysts by End of Year and Beyond
I am reposting an older post of mine to have the ability to stickie it, as I feel an updated list of some possible catalysts couldn't hurt. In my opinion, there are quite a few things we can hopefully look forward to by the end of this year, if not early to mid-way into next year.
a) The A/S increased to 2.5 Billion, yet we haven't seen this updated or heard anything about why exactly this has happened, minus the "explanation" that was told to us in the filings.
Directly from PRE 14C 8/14/18 filing: "Our board of directors has determined that it is advisable and in the best interest of the Company to increase the number of authorized shares of our Common Stock in order to ensure that the Company will satisfy its obligations under the existing convertible notes issued by the Company. We currently have 366,118,767 shares outstanding and 137,175,073 shares reserved for issuance on conversion of various outstanding securities. Since a lender is entitled to increase his reserves but has elected not to do so, there are actually no shares available for other corporate purposes and the Board does not consider this adequate for general corporate purposes. Most of our outstanding convertible securities have conversion rates based on formulas that fluctuate based on the market price of our common stock and the required reservations therefor may increase in the future if the market price for our common stock decreases. The Company would be required to issue additional shares of our Common Stock upon conversion of such convertible notes and, under certain of those convertible notes, the Company is required to have in reserve certain quantities of authorized but unissued shares of our Common Stock. Generally, with respect to the convertible notes issued by the Company, both the quantity of shares of our Common Stock that the Company would be required to issue upon conversion and the quantity of authorized but unissued shares of our Common Stock that the Company is required to have in reserve increases if the market price of our Common Stock decreases. The newly authorized shares of Common Stock would be available for issuance from time to time as determined by our board of directors for any proper purpose, which may include, without limitation, the issuance of shares in connection with financing or acquisition transactions and other corporate opportunities. We have no present plans for the issuance or reservation of additional shares of common stock other than ongoing private placements and the convertible notes referred to above.
The Company, in the ordinary course of business, considers various possible means and strategies to expand its business, which may include, among other things, possible acquisitions of complementary businesses and other businesses. At the present time, the Company has not entered into any definitive agreement with any person or entity that entails any contemplated merger, consolidation, acquisition or similar business transaction, and there are no assurances that the Company will enter into any such transaction. The increase in the number of authorized shares of Common Stock of the Company as described in this Information Statement is for the purpose of addressing the obligations under existing convertible notes issued by the Company and for other corporate purposes generally, as described in the preceding paragraph, rather for any specific contemplated transaction(s). However, we do not have any present plans or agreements for any other business which would require the issuance of any of the additional shares being authorized."
link: http://ir.endonovo.com/all-sec-filings?page=3#document-6030-0001493152-18-011633
Since then, our dilution rate has stayed the same as far as it seems, and as many have stated, it seems there may be some ulterior motive to a 5x increase. (All speculative, but should not be forgotten about) Looking to see updated OTC Page of information soon, as Craig stated it is usually updated around the end of the first week every month., that way we can confirm any change in the weekly rate.
b) The redesign of tPEMF devices for use in CNS Disorders, as that was stated to be a 2018 milestone. Specifically stated from 2018 Outlook PR that two clinical trials would be initiated, one in post-concussion syndrome and another in acute sport related concussions, both that state will initiate AFTER the redesign of these tPEMF devices.
In my opinion, since both clinical trial initiations and the redesign were slated to be a milestone of this year, I find it hard to believe that they will let the rest of 2018 go by without getting this done, or at least giving us an update on this. (They know they can get burned for not having accurate timelines) And if you are a long like me, I can imagine this is of great interest to you too. ENDV knows this redesign is critical, and I can't help but feel that we could hear something soon from this.
c) The initiation of a Pilot Clinical Trial for patients with relapsing forms of Multiple Sclerosis.
2018 Outlook PR does not state specifically whether or not this trial will commence BEFORE or AFTER the redesign. For Acute Concussions and Post Concussion Syndrome, both are specifically mentioned they will be initiated AFTER the redesign, but not for this. Since a 2018 milestone was to initiate this trial, I am also expecting to hear something pertaining to this and the redesign in the somewhat near future. Not sure if anyone has more educated input on whether or not a different device would be necessary for this.
d) Not EXPLICITLY slated to be 2018 milestone, but initiation of a clinical trial targeting Proteinuria in CKD patients.
Directly from 5/1/18 PR: "FDA Approval for the device used in the feasibility study would be necessary to secure an appropriate indication for Endonovo to market such device."
link: http://ir.endonovo.com/press-releases/detail/235/endonovo-therapeutics-highlights-feasibility-study-results
This leaves unanswered questions. From there, no plans are set forth. In the most recent annual report, a summary of methodology to enter the CNS market is laid out.
Directly from 10-K: "We are seeking to enter the CNS market via a Humanitarian Device Exemption (HDE), which is regulatory pathway for medical devices addressing rare diseases that occur in no more than 8,000 individual per year in the United States. The HDE pathway is the medical device equivalent of orphan drugs and is similar in both form and content to an FDA Pre-Market Approval (PMA). However, rather than being required to demonstrate safety and efficacy, the HDE pathway allows for medical devices to receive FDA Approval if they can demonstrate that their probable benefit outweighs their probable risk.
We will seek to enter the CNS market via a HDE for the treatment of encephalopathy in Lyme disease patients. Our FDA-Cleared Electroceutical Therapy is currently prescribed by a group of physicians to reduce neuroinflammation. We will seek to gather data from approximately 10 to 15 patients to support a Humanitarian Device Exemption from the FDA to reduce neuroinflammation in Lyme disease patients."
then, followed shortly after:
"If we are able to secure a Humanitarian Device Exemption for our Electroceutical™ Therapy from the FDA for the treatment of encephalopathy in Lyme disease patients, we will then pursue a “label expansion” strategy. This would entail entering the CNS market via the HDE pathway for the treatment of encephalopathy in Lyme disease patients and then applying to expand the label for our Electroceutical Therapy for other CNS disorders we are pursuing, including acute concussion, traumatic brain injury, post-concussion syndrome, multiple sclerosis and stoke. This strategy will require that we conduct several clinical trials simultaneously in order to fully benefit from pursuing a HDE pathway and label expansion strategy; such benefits include a potentially shorter and less costly regulatory process for our other CNS indications."
So long story short, IN MY OPINION, we are due to hear something from this entire strategy laid out, hopefully sometime in the near future. The initiation of a human clinical trial beginning in Critical Limb Ischemia definitely should not be forgotten about as well.
e) Possible Licensing, Distribution and Partnership opportunities in International Markets. Stated in 2018 outlook PR as well as 10-K as a goal. Quoted from the PR, "Endonovo plans to commercialize its CE-Marked and FDA-Cleared Electroceutical™ therapy in China, Japan, Korea and other international markets. Endonovo has already initiated dialogue with potential licensees, distributors and joint venture partners in Asia. Endonovo will further look to establish distribution agreements and licenses in the Unites States for cosmetic surgery and orthopedic indications or explore the establishment of its own sales and marketing channels."
The fact that U.S. Distribution agreements was the ladder part of this goal, and we achieved those first, gives me intuition that we hopefully should see something soon that allows us to enter these international markets.
f) (ALL SPECULATIVE) Possible submittal of ENDV's device into FDA's Innovation Challenge.
Again, all speculative, but I can't help but feel that this challenge is all but perfect for Endonovo and their business strategy. Endonovo tweeted the link to the news release at the end of August, which states that the application period is between June 1st and September 30th, and selected applicants will be announced in November.
Link to news release: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609188.htm
Directly from link above: "Developers accepted into the challenge will receive enhanced interactions with FDA review divisions during the development and evaluation of the proposed product. In addition, Breakthrough Device designation will be granted to those devices that meet the statutory criteria for designation without submission of a separate application. In most cases, The agency anticipates that applicants will eventually submit one or more formal applications to the FDA, such as an investigational device exemption, De Novo, premarket clearance (510(k)) or premarket approval application."
Fairy tale thought (maybe this could be a big key to their goals) and if by the slim chances that we were selected, I truly could not see a situation in where our PPS would not go absolutely parabolic.
And Lastly,
g) Beginning of any "redeeming of outstanding convertible notes” as Alan Collier stated in the 2018 Outlook PR.
&
h) Possible Up-List company stock onto a National Stock Exchange
Directly from 2018 Outlook PR: "Now having completed this acquisition, we are looking to position the company for continued growth by redeeming our outstanding convertible notes and uplisting the company onto a national stock exchange where we can increase shareholder value."
Obviously, I don't have a a lot of faith right now in either of these two goals, but both were still explicitly stated as goals, so again in my opinion, something to not forget about.
I feel like there is plenty that can happen at a whims notice here, and the argument that there are no catalysts to be thinking about in the near-term doesn't seem to be too accurate. Also, the continued price action is nice to see, and something still seems different than it has in any previous run, today's buy/sell volume was insane end of day, and can truly say in just shy of my 2 years of being here, I have never seen that kind of resistance blown through with minimal amount of bid support.
Anyone who thinks that this movement is just a result of these paid articles like we had today, I suggest looking at the history of Market-watch, the amount of articles that have been released on us in this manner in the past, and how they never had any kind of impact on the PPS. The only real way to see them is by searching most recent ENDV news on google, doesn't really pop up anywhere else, at least from what I have seen.
link to today's article: https://www.marketwatch.com/press-release/biotech-market-is-rolling-and-these-companies-need-to-be-on-your-radar-2018-10-02
Yes, management has not come through with things in the past.
Yes, management has not been as transparent as we may like.
Yes. there are obviously many concerns and questions going forward
Yes, there are reasons to be hesitant and doubtful here,
BUT, this being said, I don't feel like many of us are giving these guys nearly enough credit if they truly are shaping this company with a long-term mindset. If we can build a base at these higher levels over time, with the earnings outlook growth in the coming year, as well as other near-term catalysts mentioned above, I think there is plenty to be optimistic about here.
Just think this board deserves some productive chatter here again, there are still quite a few good people here, as well as a few new people I'm sure. With all the action we have had in the last couple of months, our board definitely deserves to be more a little bit more productive than this.
Looking forward to tomorrow and beyond, CHEERS!
If you can PM me your email, lets talk outside of the board. or Craig if you can PM Tk my email from what I just sent you?
Potential Catalysts by End of Year.
In my opinion, there are quite a few things we can hopefully look forward to by end of this year, if not early into next year. I wrote quite a lengthy email to Andrew/Steve yesterday with a huge list of questions and concerns, and from there, I organized what in my opinion are possible catalysts we can expect here going forward, as well as other concerns that in my opinion can help get some useful dialogue going here again, all listed below. (Still can't believe this entire few weeks of the positive move so far and there has been so little board chatter)
a) The A/S increased to 2.5 Billion, and we haven't heard anything about why exactly this has happened. Since then, our dilution rate has stayed relatively the same, and as many have stated, it seems there may be some ulterior motive to a 5x increase. (All speculative, but should not be forgotten about)
I did express much concern in my email about this and the lack of reasoning for such a dramatic change, as well as the pairing of that news with the PR of National Distribution as well.
b) The redesign of tPEMF devices for use in CNS Disorders, as that was stated to be a 2018 milestone. Specifically stated from PR that in 2018, two clinical trials would be initiated, one in post-concussion syndrome and another in acute sport related concussions, both that state will initiate AFTER the redesign of these tPEMF devices.
In my opinion, since both clinical trial initiations and the redesign were slated to be a milestone of this year, I find it hard to believe that they will let the rest of 2018 go by without getting this done, or at least giving us an update on this. (They know they can get burned for not having accurate timelines) And if you are a long like me, I can imagine this is of great interest to you too. ENDV knows this redesign is critical, and I can't help but feel that we could hear something soon from this.
c) The initiation of a Pilot Clinical Trial for patients with relapsing forms of Multiple Sclerosis.
I expressed a couple questions about this, mainly pertaining to the fact that the PR does not state specifically whether or not this trial will commence BEFORE or AFTER the redesign. For Acute Concussions and Post Concussion Syndrome, both are specifically mentioned they will be initiated after the redesign, but not for this.
Since a 2018 milestone was to initiate this trial, I am also expecting to hear something pertaining to this and the redesign in the somewhat near future. Not sure if anyone has more educated input on whether or not a different device would be necessary for this.
d) Not EXPLICITLY slated to be 2018 milestone, but initiation of a clinical trial targeting Proteinuria in CKD patients. in 5/1/18 PR about positive feasibility study results, it states,"FDA Approval for the device used in the feasibility study would be necessary to secure an appropriate indication for Endonovo to market such device."
From there, no plans are set forth. As we found out in the last annual report, (quoted directly from 10-K)
"We are seeking to enter the CNS market via a Humanitarian Device Exemption (HDE), which is regulatory pathway for medical devices addressing rare diseases that occur in no more than 8,000 individual per year in the United States. The HDE pathway is the medical device equivalent of orphan drugs and is similar in both form and content to an FDA Pre-Market Approval (PMA). However, rather than being required to demonstrate safety and efficacy, the HDE pathway allows for medical devices to receive FDA Approval if they can demonstrate that their probable benefit outweighs their probable risk.
We will seek to enter the CNS market via a HDE for the treatment of encephalopathy in Lyme disease patients. Our FDA-Cleared Electroceutical Therapy is currently prescribed by a group of physicians to reduce neuroinflammation. We will seek to gather data from approximately 10 to 15 patients to support a Humanitarian Device Exemption from the FDA to reduce neuroinflammation in Lyme disease patients."
then, followed shortly after:
"If we are able to secure a Humanitarian Device Exemption for our Electroceutical™ Therapy from the FDA for the treatment of encephalopathy in Lyme disease patients, we will then pursue a “label expansion” strategy. This would entail entering the CNS market via the HDE pathway for the treatment of encephalopathy in Lyme disease patients and then applying to expand the label for our Electroceutical Therapy for other CNS disorders we are pursuing, including acute concussion, traumatic brain injury, post-concussion syndrome, multiple sclerosis and stoke. This strategy will require that we conduct several clinical trials simultaneously in order to fully benefit from pursuing a HDE pathway and label expansion strategy; such benefits include a potentially shorter and less costly regulatory process for our other CNS indications."
So long story short, IN MY OPINION, we are due to hear something from this entire strategy laid out, hopefully sometime in the near future. The initiation of a human clinical trial beginning in Critical Limb Ischemia definitely should not be forgotten about as well.
Definitely raised much concern in my email about the fact that investors have not heard anything since positive results were released in 2/12/18 PR, and we deserve an update on exactly what the plan is for this part of the pipeline regardless.
e) Possible Licensing, Distribution and Partnership opportunities in International Markets. Stated in 2018 outlook PR as well as 10-K as a goal. Quoted from the PR, "Endonovo plans to commercialize its CE-Marked and FDA-Cleared Electroceutical™ therapy in China, Japan, Korea and other international markets. Endonovo has already initiated dialogue with potential licensees, distributors and joint venture partners in Asia. Endonovo will further look to establish distribution agreements and licenses in the Unites States for cosmetic surgery and orthopedic indications or explore the establishment of its own sales and marketing channels."
The fact that U.S. Distribution agreements was the ladder part of this goal, and we achieved those first, gives me intuition that we hopefully should see something soon that allows us to enter these international markets.
f) (ALL SPECULATIVE) Possible submittal of ENDV's device into FDA's Innovation Challenge.
Again, all speculative, but I can't help but feel that this challenge is all but perfect for Endonovo and their business strategy. Endonovo tweeted the link to the news release at the end of August, which states that the application period is between June 1st and September 30th, and selected applicants will be announced in November.
Link to news release: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609188.htm
"Developers accepted into the challenge will receive enhanced interactions with FDA review divisions during the development and evaluation of the proposed product. In addition, Breakthrough Device designation will be granted to those devices that meet the statutory criteria for designation without submission of a separate application. In most cases,
The agency anticipates that applicants will eventually submit one or more formal applications to the FDA, such as an investigational device exemption, De Novo, premarket clearance (510(k)) or premarket approval application."
I reached out about this, but for obvious reasons doubt they will be anything but tight lipped on this matter. Fairy tale thought (maybe this could be a big key to their goals) and if by the slim chances that we were selected, I truly could not see a situation in where our PPS would not go absolutely parabolic.
g) Beginning of any "redeeming of outstanding convertible notes” as Alan Collier stated in the 2018 Outlook PR.
h) Possible Up-List company stock onto a National Stock Exchange
From PR, "Now having completed this acquisition, we are looking to position the company for continued growth by redeeming our outstanding convertible notes and uplisting the company onto a national stock exchange where we can increase shareholder value."
Obviously don't have a lot of faith right now in either of these two goals, but both were still explicitly stated as goals, so again in my opinion, something to not forget about.
Both of these concerns were a very big focal point of my email, as we all know there is no realistic way an up-list can happen currently, and there is no sign of any redeeming of convertible notes happening on the horizon unfortunately. I expressed a lot about how in my opinion, Endonovo is loosing a good bit of credibility with what they say they expect and what is actually occurring (these two being perfect examples), as well as ShareIntel being another example.
From looking at PR patterns from the past, there was definitely a more solid form of transparency via PR's at least, in terms of note and financing information. I addressed this, as well as the continual spending of $70,000 on "paid market awareness" articles that get released, and how as a long term investor, these give much less confidence in the company than more PR's would do that simply address some updates on a few of their endeavors, and spending more money on actually getting their data more heavily into the scientific community, via possible meetings and relevant conferences. (Another thing stated last year, I asked for an update on this as well)
I feel like there is plenty that can happen at a whims notice here, and the argument that there are no catalysts to be thinking about in the near-term doesn't seem to be too accurate. Also, the continued price action is nice to see, and something still seems different than it has in the past, today's buy/sell volume was a nice sight.
Would love input from any of you on more concerns/questions I am forgetting about that can be asked and discussed here as well! PM me your email if interested in hearing a little bit more about what I hear back, not really wanting to share all that on the board. Point of this is to get people thinking and emailing the company themselves with these concerns. The more we press IR, the more likelihood of us getting an update in return. It was cool to see that Andrew is taking my questions to management as he wants to answer them accurately. (told me this early today) Either way, they are responsive and I for one can definitely appreciate that.
Dont want to jinx it... but we are holding up decently at these levels.